Acute toxic effects of ‘Ecstasy’ (MDMA) and related compounds: overview of pathophysiology and clinical management[1]
Summary
This overview covers the pharmacology and acute toxic effects of 'Ecstasy' (3,4-methylenedioxymethamphetamine, MDMA) and related compounds, followed by a plan for clinical management. It states that since the late 1980s MDMA has become established as a popular recreational drug in western Europe. It cites a UK National Criminal Intelligence Service estimate that 0.5 to 2 million tablets are consumed weekly in Britain, and a report that 4.5 percent of young adults aged 15 to 34 years in the UK had used MDMA in the previous 12 months. The article says clinically important toxic effects have been reported, including fatalities, and that while hyperpyrexia and multi-organ failure are now relatively well known, other serious effects have become apparent more recently. It notes that patients with acute MDMA toxicity may present to doctors working in anaesthesia, intensive care and emergency medicine, so broad knowledge of these pathologies and their treatment is necessary in any acute specialty.
So what
For festival and concert medical teams this supports building MDMA toxicity explicitly into on-site protocols, with hyperpyrexia and multi-organ failure named as the recognised severe presentations requiring rapid escalation. The consumption and prevalence figures describe Britain in that period and are not event-level data, so they justify preparedness rather than predicting caseload at any particular gathering.
Read the paper
- Publisher (DOI) ↗may be paywalled